Placing the Right Bets: Defining Tailored Investment Strategies for Pharma Launch
Pharmaceutical launches have become significantly harder to execute successfully. As IQVIA’s new white paper highlights, “median six month cumulative sales for innovative launches have declined by 23% compared with pre 2020 levels,” reflecting shrinking market opportunities, more complex care pathways, and increasingly crowded therapeutic landscapes. In this environment, traditional launch investment models—often tied to peak sales heuristics or past launch costs—no longer provide reliable guidance.
IQVIA’s white paper outlines that pharma companies must rethink how they allocate operational expenditure (OPEX) across Medical, Market Access, Sales & Marketing, Patient Support, and Real World Evidence to support drug launches. An archetype led approach is proposed that aligns investment decisions with the scientific, clinical, and competitive realities of each launch rather than relying on one-size-fits-all assumptions.
Why Launch Investment Planning Needs a New Framework
The paper frames launch planning around three essential questions:
- How much to invest relative to expected revenues and strategic priorities
- When to invest, especially how early pre launch activities should begin
- Where to invest across functions and channels
These questions have become more complex as companies launch in new therapeutic areas, compete in saturated markets, and navigate emerging disease ecosystems such as obesity, MASH, or Alzheimer’s disease. The authors note that “more medicines are entering smaller, more fragmented and complex markets,” making tailored investment strategies essential.
Four Archetypes That Define Launch Needs
Based on analysis of approximately 100 launches, IQVIA identifies four archetypes shaped by four factors: Maturity of the care pathway, scientific complexity, demand generation model, and competitive intensity. Each archetype requires a distinct investment pattern.
1. Share of Voice
For mature, highly competitive markets—such as diabetes, immunology, and cardiovascular disease—success depends on broad promotional reach. Differentiation often relies “less on clinical distinction than on sustained promotional efforts.” Investment peaks at launch and remains high, with significant emphasis on sales force activity and advertising.
2. Science Led
These launches involve novel mechanisms or biomarker driven therapies, common in oncology and neurology. Uptake depends on scientific credibility, early evidence generation, and specialist engagement. Investment begins years before launch, with a heavy tilt toward medical education and market shaping.
3. Ecosystem Building
In emerging therapy areas without established pathways—such as obesity, MASH, or Alzheimer’s—companies must invest early to shape diagnostics, reimbursement, and care models. The paper contrasts the rapid adoption of GLP 1s with the slower uptake of Alzheimer’s treatments to illustrate how system readiness determines success.
4. CoE Focused
Rare disease launches require deep engagement with a small number of Centres of Excellence. Pre launch investment is high, focused on diagnosis, referral pathways, and personalised patient support, while sales and marketing remain lean.
Investment Trajectories: Timing Matters as Much as Budget
Each archetype follows a distinct OPEX curve. Science led and ecosystem building launches require the earliest and most substantial pre launch investment. Share of voice launches peak at launch, while CoE focused launches concentrate resources on early medical groundwork. Country level differences—such as the prominence of field forces or the ability to use direct to consumer advertising—further shape investment patterns.
The Strategic Imperative: Spend Smarter, Not More
The white paper concludes that success in today’s fragmented launch environment depends on intentional, evidence based investment. As the authors write, “success will come not from spending more but from spending smarter—investing with intent by placing the right bets at the right time in the right places.”
This archetype driven framework offers pharma leaders a practical, data backed way to align resources with real world launch dynamics and build the foundations for sustainable growth.
Download '.pdf' Format of the whitepaper.
